Related references
Note: Only part of the references are listed.Treatment-Free Remission After Second-Line Nilotinib Treatment in Patients With Chronic Myeloid Leukemia in Chronic Phase
Francois-Xavier Mahon et al.
ANNALS OF INTERNAL MEDICINE (2018)
Myeloid-derived suppressor cells coming of age
Filippo Veglia et al.
NATURE IMMUNOLOGY (2018)
A prospective analysis of symptom burden for patients with chronic myeloid leukemia in chronic phase treated with frontline second- and third-generation tyrosine kinase inhibitors
Alejandro Zulbaran-Rojas et al.
CANCER MEDICINE (2018)
Increased proportion of mature NK cells is associated with successful imatinib discontinuation in chronic myeloid leukemia
M. Ilander et al.
LEUKEMIA (2017)
Long-Term Follow-Up of the French Stop Imatinib (STIM1) Study in Patients With Chronic Myeloid Leukemia
Gabriel Etienne et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Expression of the CTLA-4 ligand CD86 on plasmacytoid dendritic cells (pDC) predicts risk of disease recurrence after treatment discontinuation in CML
C. Schuetz et al.
LEUKEMIA (2017)
Immune Effector Recovery in Chronic Myeloid Leukemia and Treatment-Free Remission
Amy Hughes et al.
FRONTIERS IN IMMUNOLOGY (2017)
CML patients with deep molecular responses to TKI have restored immune effectors and decreased PD-1 and immune suppressors
Amy Hughes et al.
BLOOD (2017)
Targeting YAP-Dependent MDSC Infiltration Impairs Tumor Progression
Guocan Wang et al.
CANCER DISCOVERY (2016)
Prognostic Significance of Monocytes and Monocytic Myeloid-Derived Suppressor Cells in Diffuse Large B-Cell Lymphoma Treated with R-CHOP
Chongyang Wu et al.
CELLULAR PHYSIOLOGY AND BIOCHEMISTRY (2016)
Life Expectancy of Patients With Chronic Myeloid Leukemia Approaches the Life Expectancy of the General Population
Hannah Bower et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Multiple myeloma exosomes establish a favourable bone marrow microenvironment with enhanced angiogenesis and immunosuppression
Jinheng Wang et al.
JOURNAL OF PATHOLOGY (2016)
The Nature of Myeloid-Derived Suppressor Cells in the Tumor Microenvironment
Vinit Kumar et al.
TRENDS IN IMMUNOLOGY (2016)
Immunology of chronic myeloid leukemia: current concepts and future goals
Vladimir Vonka et al.
EXPERT REVIEW OF CLINICAL IMMUNOLOGY (2015)
Myeloid-derived suppressor cells in the tumor microenvironment: expect the unexpected
Douglas Marvel et al.
JOURNAL OF CLINICAL INVESTIGATION (2015)
The Tyrosine Kinase Inhibitors Imatinib and Dasatinib Reduce Myeloid Suppressor Cells and Release Effector Lymphocyte Responses
Lisa Christiansson et al.
MOLECULAR CANCER THERAPEUTICS (2015)
Relative survival in patients with chronic-phase chronic myeloid leukaemia in the tyrosine-kinase inhibitor era: analysis of patient data from six prospective clinical trials
Koji Sasaki et al.
LANCET HAEMATOLOGY (2015)
Discontinuation of dasatinib in patients with chronic myeloid leukaemia who have maintained deep molecular response for longer than 1 year (DADI trial): a multicentre phase 2 trial
Jun Imagawa et al.
LANCET HAEMATOLOGY (2015)
BCR-ABL1-positive microvesicles transform normal hematopoietic transplants through genomic instability: implications for donor cell leukemia
X. Zhu et al.
LEUKEMIA (2014)
Extracellular vesicles: Exosomes, microvesicles, and friends
Graca Raposo et al.
JOURNAL OF CELL BIOLOGY (2013)
Association of an increased frequency of CD14+HLA-DRlo/neg monocytes with decreased time to progression in chronic lymphocytic leukaemia (CLL)
Michael P. Gustafson et al.
BRITISH JOURNAL OF HAEMATOLOGY (2012)
Tumor-derived microvesicles: shedding light on novel microenvironment modulators and prospective cancer biomarkers
Crislyn D'Souza-Schorey et al.
GENES & DEVELOPMENT (2012)
Health-related quality of life in chronic myeloid leukemia patients receiving long-term therapy with imatinib compared with the general population
Fabio Efficace et al.
BLOOD (2011)
Patients with chronic myeloid leukemia who maintain a complete molecular response after stopping imatinib treatment have evidence of persistent leukemia by DNA PCR
D. M. Ross et al.
LEUKEMIA (2010)
Myeloid-derived suppressor cells as regulators of the immune system
Dmitry I. Gabrilovich et al.
NATURE REVIEWS IMMUNOLOGY (2009)
Share Paper
